PRKAA2 and rhabdomyosarcoma: The results from this study not only verify the previously reported anti-tumorigenic properties of curcumin in rhabdomyosarcoma, but they also open the door to the testing of small molecule inhibitors to AMPK, PI3K/AKT/mTOR, STAT, and p53, individually or in combination depending on the characteristics of the rhabdomyosaroma in question (ARMS or ERMS, wt p53, or mut p53), in vitro and in vivo.